Rapid Micro Biosystems | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 7.838 M

LB filings
2025.11.07 22:09
portai
I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q3, the actual value is USD 7.838 M, beating the estimate of USD 7.6 M.

EPS: As of FY2025 Q3, the actual value is USD -0.26, missing the estimate of USD -0.245.

EBIT: As of FY2025 Q3, the actual value is USD -11.33 M.

Segment Revenue

  • Product Revenue: $5,214,000 for the three months ended September 30, 2025, compared to $5,255,000 for the same period in 2024, a decrease of 0.8%.
  • Service Revenue: $2,624,000 for the three months ended September 30, 2025, compared to $2,349,000 for the same period in 2024, an increase of 11.7%.

Operational Metrics

  • Net Loss: $11,505,000 for the three months ended September 30, 2025, compared to $11,323,000 for the same period in 2024, an increase of 1.6%.
  • Gross Margin: Positive gross margins maintained since the third quarter of 2024.
  • Operating Expenses: Total costs and operating expenses were $19,210,000 for the three months ended September 30, 2025, compared to $19,643,000 for the same period in 2024, a decrease of 2.2%.

Cash Flow

  • Net Cash Used in Operating Activities: $27,816,000 for the nine months ended September 30, 2025, compared to $34,244,000 for the same period in 2024.
  • Net Cash Provided by Investing Activities: $10,442,000 for the nine months ended September 30, 2025, compared to $31,794,000 for the same period in 2024.
  • Net Cash Provided by Financing Activities: $19,328,000 for the nine months ended September 30, 2025, compared to $209,000 for the same period in 2024.

Unique Metrics

  • Systems Placed: 5 systems placed in the three months ended September 30, 2025, compared to 7 systems in the same period in 2024, a decrease of 28.6%.
  • Cumulative Systems Placed: 174 systems as of September 30, 2025, compared to 156 systems as of September 30, 2024, an increase of 11.5%.

Future Outlook and Strategy

  • Core Business Focus: The company aims to achieve positive cash flow by the end of 2027, focusing on reducing cash use for operating and investing activities.
  • Non-Core Business: The company entered into a Distribution and Collaboration Agreement with MilliporeSigma to expand its market reach globally, with a focus on industrial quality control applications.
  • Priority: The company is prioritizing the expansion of its Growth Direct platform and increasing customer adoption, with a strategic focus on biologics and cell and gene therapies.
Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.